NCT07033962

Brief Summary

To evaluate the efficacy and safety of topical fluconazole microemulsion enhanced by fractional CO₂ laser versus by 40% urea ablation in treatment of Onychomycosis.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
2mo left

Started Jun 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Jun 2025Jul 2026

First Submitted

Initial submission to the registry

May 26, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
23 days until next milestone

First Posted

Study publicly available on registry

June 24, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

1 year

First QC Date

May 26, 2025

Last Update Submit

June 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • comparison effect of fractioal co2 laser and 40% urea assisted delivery of topical fluconazole microemulsion in onychomycosis

    Onychomycosis Severity Index (OSI) score will be assessed for each patient Points were given based on : 1. The percentage of nail involvement (0-5points) 0% 0 point 1-10% 1 point 11-25% 2 points 26-50% 3 points 51-75% 4 points 76-100% 5 points 2. Proximity of disease to matrix (1-5 points) \<25% 1 point, 25-50% 2 points ,50-75% 3 points, \>75% 4 point, Matrix involvement 5 points 3. Dermatophytoma or subungual hyperkeratosis \> 2 mm. Present 10 points, Absent 0 points The score will be calculated by this equation: \[Score for percentage of involvement \* Score for the proximity of disease to the matrix + Score for dermatophytoma or subungual hyperkeratosis \> 2 mm\] Then the onychomycosis is classified as mild (1-5 points), moderate (6-15 points) or severe (16-35 points), zero indicates cured

    one month after end of treatment

Study Arms (2)

Fractional Co2 laser

EXPERIMENTAL

Combination Product:" Fractional CO2 laser" and "topical fluconazole microemulsion"

Combination Product: "Fractional CO2 laser" and "topical fluconazole microemulsion"

Urea 40%

EXPERIMENTAL

Combination Product: "Urea 40%" and "topical fluconazole microemulsion"

Combination Product: "Urea 40%" and "topical fluconazole microemulsion"

Interventions

four sessions of fractional CO2 at 3weeks interval with a laser device (multixel, Daeshin enterprise co., LTD. (D.S.E) 105, 271, digital -ro, Guro-gu, Seoul, Koreaa) at a pulse energy of 140 mJ, a density of 150 spots/ cm2 and a depth of 1 cm combined with twice daily topical fluconazole microemulsion.

Fractional Co2 laser

urea 40% paste under occlusion once daily over 4 weeks followed by topical fluconazole microemulsion twice daily for 8 weeks.

Urea 40%

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinically and mycologically confirmed onychomycosis
  • No topical antifungal use in the past 1 month
  • No systemic antifungal use in the past 3 months

You may not qualify if:

  • pregnancy or lactation
  • Nail disorders such as psoriasis, eczema, lichen planus
  • patients have a known allergy to any of the study treatments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Onychomycosis

Condition Hierarchy (Ancestors)

TineaDermatomycosesMycosesBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousNail DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Shaza alaa abdelmoneim

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

May 26, 2025

First Posted

June 24, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

June 29, 2025

Record last verified: 2025-06